Jade Biosciences (JBIO) Other Non-Current Liabilities (2021 - 2025)
Jade Biosciences (JBIO) posted Other Non-Current Liabilities of $70000.0 for Q1 2025, down 99.93% on a QoQ basis from $107.6 million in Q4 2024, and little changed year-over-year from $70000.0 in Q1 2024.
Jade Biosciences (JBIO) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
Jade Biosciences' Other Non-Current Liabilities history runs 5 years deep, the most recent figure standing at $70000.0 for Q1 2025.
- Quarterly Other Non-Current Liabilities changed 0.0% year-over-year to $70000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $70000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $107.6 million, up 153614.29% from the prior year.
- Other Non-Current Liabilities was $70000.0 for Q1 2025 at Jade Biosciences, down from $107.6 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $107.6 million in Q4 2024 and bottomed at $13000.0 in Q4 2021.
- A 5-year average of $7.7 million and a median of $70000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2023 — Other Non-Current Liabilities decreased 1.41% — and 2024, when it jumped 153614.29%.
- Jade Biosciences' Other Non-Current Liabilities stood at $13000.0 in 2021, then surged by 446.15% to $71000.0 in 2022, then slipped by 1.41% to $70000.0 in 2023, then soared by 153614.29% to $107.6 million in 2024, then tumbled by 99.93% to $70000.0 in 2025.
- Business Quant data shows JBIO's Other Non-Current Liabilities at $70000.0 in Q1 2025, $107.6 million in Q4 2024, and $70000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Jade Biosciences | 16.25 Mn | 16.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 70,000.00 |
| Dec 31, 2024 | 107.60 Mn |
| Sep 30, 2024 | 70,000.00 |
| Jun 30, 2024 | 70,000.00 |
| Mar 31, 2024 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 69,000.00 |
| Mar 31, 2023 | 70,000.00 |
| Dec 31, 2022 | 71,000.00 |
| Sep 30, 2022 | 13,000.00 |
| Jun 30, 2022 | 13,000.00 |
| Mar 31, 2022 | 14,000.00 |
| Dec 31, 2021 | 13,000.00 |